MedTrace Logo

SAD/MAD Study of a New Formulation of Nebulised RPL554 in Healthy Subjects and COPD Subjects

NCT02307162 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2015-10-28

No results posted yet for this study

Summary

The purpose of the study is to assess the safety of single doses and multiple doses of a new formulation of RPL554 in healthy subjects and subjects with chronic obstructive pulmonary disorder.

Conditions

  • Inflammatory Disorder of the Respiratory Tract
  • Chronic Obstructive Pulmonary Disorder

Interventions

DRUG

RPL554

Phosphodiesterase 3 and 4 Inhibitor

DRUG

Placebo

Dummy solution

Sponsors & Collaborators

  • Verona Pharma plc

    lead INDUSTRY

Principal Investigators

  • Dave Singh · Medicines Evaluation Unit, Manchester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02307162 on ClinicalTrials.gov